ONCTERNAL THERAPEUTICS INC (ONCT)
US68236P2065 - Common Stock
Overall ONCT gets a fundamental rating of 2 out of 10. We evaluated ONCT against 588 industry peers in the Biotechnology industry. ONCT has a great financial health rating, but its profitability evaluates not so good. ONCT does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year ONCT has reported negative net income.
In the past year ONCT has reported a negative cash flow from operations.
ONCT had negative earnings in each of the past 5 years.
ONCT had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -107.50%, ONCT is doing worse than 79.62% of the companies in the same industry.
ONCT's Return On Equity of -131.39% is on the low side compared to the rest of the industry. ONCT is outperformed by 61.13% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -107.5% | ||
| ROE | -131.39% | ||
| ROIC | N/A |
ROA(3y)-68.42%
ROA(5y)-75.46%
ROE(3y)-79.78%
ROE(5y)-98.74%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for ONCT so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ONCT has less shares outstanding than it did 1 year ago.
The number of shares outstanding for ONCT has been reduced compared to 5 years ago.
There is no outstanding debt for ONCT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -8.06, we must say that ONCT is in the distress zone and has some risk of bankruptcy.
ONCT has a worse Altman-Z score (-8.06) than 72.60% of its industry peers.
There is no outstanding debt for ONCT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -8.06 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 6.94 indicates that ONCT has no problem at all paying its short term obligations.
ONCT has a Current ratio of 6.94. This is in the better half of the industry: ONCT outperforms 67.64% of its industry peers.
A Quick Ratio of 6.94 indicates that ONCT has no problem at all paying its short term obligations.
With a decent Quick ratio value of 6.94, ONCT is doing good in the industry, outperforming 67.81% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.94 | ||
| Quick Ratio | 6.94 |
3. Growth
3.1 Past
The earnings per share for ONCT have decreased strongly by -191.16% in the last year.
The Revenue for ONCT has decreased by -47.18% in the past year. This is quite bad
Measured over the past years, ONCT shows a very negative growth in Revenue. The Revenue has been decreasing by -38.53% on average per year.
EPS 1Y (TTM)-191.16%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q22.25%
Revenue 1Y (TTM)-47.18%
Revenue growth 3Y-38.53%
Revenue growth 5YN/A
Revenue growth Q2Q74.71%
3.2 Future
The Earnings Per Share is expected to grow by 14.82% on average over the next years. This is quite good.
The Revenue is expected to decrease by -14.87% on average over the next years. This is quite bad
EPS Next Y12.99%
EPS Next 2Y10.73%
EPS Next 3Y25.03%
EPS Next 5Y14.82%
Revenue Next Year-52.27%
Revenue Next 2Y-2.29%
Revenue Next 3Y6.07%
Revenue Next 5Y-14.87%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ONCT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ONCT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
ONCT's earnings are expected to grow with 25.03% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.73%
EPS Next 3Y25.03%
5. Dividend
5.1 Amount
No dividends for ONCT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ONCTERNAL THERAPEUTICS INC
NASDAQ:ONCT (4/26/2024, 7:08:04 PM)
After market: 9.36 +1.07 (+12.91%)8.29
+0.04 (+0.48%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap24.54M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -107.5% | ||
| ROE | -131.39% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 6.94 | ||
| Quick Ratio | 6.94 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-191.16%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y12.99%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-47.18%
Revenue growth 3Y-38.53%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y